20.500.12556/DiRROS-29208 Primary vitreoretinal lymphoma diagnostic and therapeutic insights from a Slovenian population-based study Background: This study aimed to determine the national incidence, characterize clinical features, and evaluate the treatment outcomes of primary vitreoretinal lymphoma (PVRL) in Slovenia. Methods: We conducted a population-based, retrospective case series of all patients diagnosed with PVRL at the Eye Hospital, University Medical Center Ljubljana, between January 2013 and May 2024. The diagnosis was histopathologically confirmed, and primary central nervous system involvement was excluded. Clinical presentation, diagnostic delay, treatment modality, and adverse events were analyzed. Progression-free survival (PFS), overall survival (OS), and lymphoma-specific survival (LSS) were calculated. Results: Twelve patients were diagnosed with PVRL (four men, eight women; median age of 76 years). The average annual incidence was 0.52 cases per million. The median time from symptom onset to diagnosis was 238 days. The two most common symptoms were decreased visual acuity (75%) and floaters (58%). Vitreous cellular infiltration was the predominant clinical sign and was observed in 92% of patients. Five patients presented with unilateral disease, seven with bilateral disease, and three with unilateral disease that progressed to bilateral involvement. The median follow-up was 31.5 months. Eleven patients received one or more treatment modalities: intravitreal rituximab and/or methotrexate, local radiotherapy, and/or systemic chemotherapy. Local remission was achieved in all treated eyes. Two cases of granulomatous uveitis occurred during intravitreal rituximab therapy. The median PFS was 12 months; the two- and three-year PFS rates were 37.5% and 18.8%, respectively. The median OS was not reached; the two- and three-year OS rates were 70% and 56%, respectively. The LSS was 80% at two years and 64% at three years. Conclusions: This Slovenian population-based study provides real-world insights into PVRL management. In elderly and medically fragile patients, local treatment modalities provided effective ocular disease control with acceptable toxicity. methotrexate population-based study primary vitreoretinal lymphoma radiotherapy survival analysis metotreksat populacijska študije primarni vitreoretinalni limfom radioterapija analiza preživetja true false true Angleški jezik Slovenski jezik Neznano 2026-04-24 13:44:32 2026-04-24 13:44:32 2026-04-25 03:53:42 0000-00-00 00:00:00 2026 0 0 Nasl. z nasl. zaslona; Opis vira z dne 22. 4. 2026; str. 1-32 iss. 1, [article no.] 65 Vol. 12 2026 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 617.7-006 2056-9920 10.1186/s40942-026-00830-5 276112643 RAZ_Vrabic_Nika_2026.pdf RAZ_Vrabic_Nika_2026.pdf 1 F25314E6C4751A81A98BA1F2B45398C4 5bc1f5baeb737a02380bb1554b03bbd9bc69bd63b92fd91bc9896cca3815f539 149f2d45-3fd3-11f1-ad5f-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=43684 https://link.springer.com/article/10.1186/s40942-026-00830-5 1 f979ec0d-3fd2-11f1-ad5f-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=43683 Univerzitetni klinični center Ljubljana 0 0 0